About Event
Welcome to the 8th Dermatology Drug Development Summit
Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit!
If you are interested in the 2025 event, please get in touch at info@hansonwade.com
The 8th Dermatology Drug Development Summit was the definitive industry-led forum uniting a driven community trailblazing innovative drug discovery research and clinical strategy to collectively improve the long-term quality of life for patients with immuno-inflammatory disease.
Recognizing how disease heterogeneity and biomarker discovery is triggering a new wave of novel drug discovery efforts while clinical pipelines see increasing competition, staying ahead of the curve to develop differentiated candidates for novel inflammatory candidates had never been more important.
Showcasing the most novel targets, modalities, MoA and delivery approaches, 2024 brought you:
 |
4 deep-dive workshops on progressing emerging candidates for Hidradenitis Suppurativa, JAK Inhibitor MoA, Indication Expansion Strategies, and Navigating Clinical Patient Recruitment & Retention Challenges |
|
Increased content from 30+ organizations to effectively map the drug development landscape, including clinical pipeline case studies including dedicated Q&A time with Johnson & Johnson, Innovative Medicine, LEO Pharma, Sanofi and InflaRx to define pipeline strategies with late-stage programs in mind |
|
Novel targets & translational techniques: we discovered research techniques driving immunologic heterogeneity and pathogenesis discoveries to uncover new therapeutic opportunities then translate to the clinic through novel models and assays with advanced predictive power in chronic disease |
|
Clinical & commercial strategy: we uncovered creative clinical design with defined endpoints to hasten timelines, whilst demonstrating safety, efficacy and long-term improvements in QoL for Best-In-Class approvals |